Helix BioPharma (TSE:HBP),which is developing candidates for preventing and treating cancer, has started enrolling the next cohort under its phase I/II clinical study.
Helix BioPharma (),which is developing candidates for preventing and treating cancer, has started enrolling the next cohort under its phase I/II clinical study.
It is now screening patients for the 15th dose level cohort in the ongoing study for safety, tolerability and preliminary efficacy L-DOS47 in Poland.
L-DOS47 is currently being evaluated in two clinical studies - Poland and in the US- as a treatment for certain patients with non-small cell lung cancer.
The Trial Steering Committee has completed the safety review of cohort 14 and recommended that Helix begin enrollment of patients into the fifteenth (15) cohort.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE